HC Wainwright Starts Coverage of Agios Pharmaceuticals with Buy Rating
HC Wainwright & Co. has begun analyst coverage of Agios Pharmaceuticals shares with a Buy rating, according to Dow Jones Newswires.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Dow Jones Newswires reports that HC Wainwright & Co. has started covering Agios Pharmaceuticals shares and assigned them a Buy rating.
The original material points to Benzinga's analyst ratings page for details on rating actions.
why it matters
Initiation news for a single stock usually concerns only the company itself and rarely moves the broader market. For investors, it is one additional reference point when studying the shares.
tags
instruments
sources
- Agios Pharmaceuticals Coverage Assumed by HC Wainwright & Co. at Buy — Dow Jones Newswires, 29 October 2026 at 13:26 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗